Laboratory tests show that even the half-dose currently authorized raises antibodies by 37 times but it is not yet known for how long. The company intends to focus on the recall
A booster dose of Moderna’s coronavirus vaccine significantly increases the level of antibodies which can counter the variant of Omicron. This was announced by the American company in a statement. good news coming in the days when Omicron is advancing rapidly around the world, even causing infections among those who have finished the vaccination course.
The results show that the currently authorized booster dose of 50 micrograms (half of the dose administered for the primary vaccination course in which each single dose of 100 micrograms) has increased the level of antibodies by about 37 times. A full dose of 100 micrograms proved even more powerful, increasing the levels of antibodies by about 83 times
compared to pre-boost levels. The data has not yet been published or reviewed by independent experts, however Moderna had already communicated in recent days that it was preparing the work to be published online
Both doses caused side effects comparable to those observed after the first vaccination course, but the 100 microgram dose showed slightly more frequent adverse reactions than the authorized 50 microgram dose.
The results are based on t
East laboratory which measure only the presence of neutralizing antibodies, without investigating cellular immunity (presence of T and B lymphocytes) against the virus. Although vaccines cannot prevent infection from the variant (they are not neutralizing and were created to prevent the serious consequences of the virus), there they are expected to prevent severe disease in the vast majority of people.
Moderna tested the booster on 40 people, 20 for each type of dose. Before the booster all volunteers had low levels of antibodies which can prevent Omicron infection. A month after the booster there was a marked increase in antibodies. In detail, the half dose increased the neutralizing antibody titers against Omicron to 850, which is 37 times higher than the pre-boost levels. With the full dose the neutralizing antibody titers against Omicron rose to 2228, which is approximately 83 times higher than the pre-boost levels.
Based on the findings, a note reads, given the strength of the neutralizing antibody titers generated by the current vaccine mRNA-1273 and given the rapid pace of expansion of Omicron and the greater complexity of the distribution of a new vaccine, theThe company will focus its short-term efforts on the mRna-1273 booster to tackle the new mutant.
Given the long-term threat demonstrated by Omicron’s immune leak, Moderna however, it will also continue to develop a vaccine
specifically against the Omicron variant which is expected to be ready for clinical trials in early 2022 and will consider including Omicron in its multivalent booster program.
Pfizer also said last week that the third dose (30 micrograms) indicates a 25-fold increase in antibody levels compared to those detected three weeks after the second dose. The ability to neutralize Omicron remains high, although lower than Delta. Preliminary data from the UK showed around 70% effectiveness of the Pfizer vaccine after the third dose and around 20% -40% after the second dose.
For both boosters it is not yet known how long the protection will last. A German team on Israeli data in the laboratory found a rapid decline in efficacy after three months of the Pfizer vaccine. To find out, however, we must wait for the data on the real world.
December 20, 2021 (change December 20, 2021 | 16:21)
© REPRODUCTION RESERVED
#full #dose #Moderna #vaccine #increases #antibodies #Omicron #times #company #announced